Harvest One Cannabis Inc., of Vancouver, British Columbia, through its wholly owned subsidiary, Satipharm AG, said its capsules were used in a phase II trial by Phytotech Therapeutics Ltd., a wholly owned subsidiary of MMJ Phytotech Ltd., of Nedlands, Australia. Read More
Biopontis Alliance for Rare Diseases, a nonprofit organization, of Raleigh, N.C., and Massachusetts General Hospital (MGH) reported that they will collaborate to target Huntington's disease. Read More
Aequus Pharmaceuticals Inc., of Vancouver, British Columbia, completed the equity financing of 1 million units priced at 30 cents per unit for aggregate gross proceeds of $300,000. Read More
Drug prices often are the go-to target when it comes to grappling with the growth of health spending in the U.S. But rather than blaming one sector or another, policy-makers need to go below the surface to explore the tough issues that can lead to change, Robert Dubois, chief science officer and executive vice president of the National Pharmaceutical Council (NPC), said Thursday at a forum on health spending. Read More
The elucidation of the detailed three-dimensional (3-D) atomic structure of a key drug receptor will facilitate the design of new polypharmacology drugs capable of acting on multiple targets, opening up new ways to develop drugs for the treatment of complex diseases. Read More
DUBLIN – Syndesi Therapeutics SA, a newly formed UCB SA spinout, closed €17 million (US$21.2 million) in a series A round to take forward a novel series of synaptic vesicle protein 2A (SV2A) modulators for treating dementia. Read More
The Medicines Co.'s brisk enrollment of the confirmatory, phase III, 1,500-patient Orion-11 trial with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor inclisiran not only bodes well for the firm but may say something about the already approved therapies in the class as well. Read More
Avrobio Inc. has completed a $60 million series B financing expected to support multiple gene therapies from the company's lentiviral platform, including its lead candidate, AVR-RD-01, currently in phase I for Fabry disease. Read More
Corcept Therapeutics Inc., of Menlo Park, Calif., reported preliminary fourth-quarter revenue of $53.3 million, and preliminary 2017 revenue of $159.2 million, nearly doubling the 2016 revenue of $81.3 million. Read More
